Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The report details a specific share repurchase transaction executed on February 9, 2011, under authority granted by shareholders at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 1,480,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,188.0 pence; lowest price paid was 1,169.0 pence.
- Treasury Holdings (Settled): 475,092,284 shares (8.38% of total issued share capital).
- Treasury Holdings (Including Unsettled): 478,837,284 shares (9.22% of total voting rights).
- Shares in Issue: 5,195,672,446 shares (excluding treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,480,000 shares. This transaction increased the proportion of shares held in Treasury from the prior level to 8.38% of issued capital (9.22% of voting rights including unsettled shares).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The stated intent is to hold the repurchased shares in Treasury.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (475,092,284 settled) against the company's latest capitalization table.
- Confirm the total voting rights denominator (5,195,672,446 shares) for disclosure threshold calculations under Financial Services Authority rules.
- Review the average price paid per share relative to the market price on February 9, 2011.
- Check subsequent filings for the settlement status of the 3,745,000 shares included in the "including shares which have been purchased but not yet settled" figure.